SCHEMBL760836

SCHEMBL760836

CC(C)(C)OC(=O)N1CCC(C#N)(c2ccccn2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 7/20 0.50
JAK1 P23458 7/20 0.50
GPR119 Q8TDV5 3/20 0.50
GRM5 P41594 1/20 0.47
POLB P06746 1/20 0.46
ADRA1A P35348 1/20 0.46
OPRD1 P41143 1/20 0.45
OPRK1 P41145 1/20 0.45
HSD11B1 P28845 1/20 0.44
SPR P35270 1/20 0.44
PRKCA P17252 1/20 0.43
PTPN2 P17706 1/20 0.43
HTR7 P34969 1/20 0.43
DTYMK P23919 1/20 0.43
CYP3A4 P08684 2/20 0.42
CYP2D6 P10635 2/20 0.42
HSD17B10 Q99714 2/20 0.42
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30017613 1.00 JAK2 (0.50) JAK2JAK1GPR119GRM5POLB
SCHEMBL5874046 0.93 JAK2 (0.47) JAK2JAK1GPR119GRM5POLB
SCHEMBL25261319 0.88 GPR119 (0.50) JAK2JAK1GPR119GRM5POLB
SCHEMBL3886709 0.88 GPR119 (0.46) JAK2JAK1GPR119GRM5POLB
SCHEMBL30936178 0.87 GPR119 (0.44) JAK2JAK1GPR119GRM5POLB
SCHEMBL18702094 0.84 ADRA1A (0.48) JAK2JAK1ADRA1AOPRD1HSD11B1
SCHEMBL3048650 0.84 JAK2 (0.45) JAK2JAK1GPR119POLB
SCHEMBL18353567 0.84 JAK2 (0.50) JAK2JAK1GPR119
SCHEMBL6891011 0.83 JAK2 (0.45) JAK2JAK1GPR119POLB
SCHEMBL11963487 0.83 JAK2 (0.47) JAK2JAK1GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4653438-A1 MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2025-11-26 EP disclosed
US-20240383853-A1 OXIMES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES Zevra Denmark A/S (DK) 2024-11-21 US disclosed
WO-2024153208-A9 MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF 劲方医药科技(上海)有限公司 2024-08-22 WO disclosed
WO-2024153208-A1 MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF 劲方医药科技(上海)有限公司 2024-07-25 WO disclosed
CN-118139842-A Oximes and their use in the treatment of GBA related diseases 泽拉丹麦有限公司 2024-06-04 CN disclosed
US-20230348467-A1 Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2023-11-02 US disclosed
US-20230348467-A1 Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2023-11-02 US disclosed
US-20230348467-A1 Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2023-11-02 US disclosed
US-11584765-B2 Polycyclic amines as sigma receptor modulators Ecstasy LLC (US) 2023-02-21 US disclosed
CN-110662541-B Polycyclic amines as opioid receptor modulators 王晓冬 2023-02-10 CN disclosed
WO-2005094514-A2 HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS MERCK & CO., INC. (US) 2005-10-13 WO disclosed
WO-2005051390-A1 E-FLUORO-4-(PYRIDIN-2-YL)-PIPERIDINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN MERCK SHARP & DOHME LIMITED (GB) 2005-06-09 WO disclosed
US-5861416-A TREATMENT OF ASTHMA OR COUGH MERRELL PHARMACEUTICALS INC. (US) 1999-01-19 US disclosed
US-5824690-A TREATING ASTHMA, COUGH HOECHST MARION ROUSSEL INC. (US) 1998-10-20 US disclosed
EP-0696280-B1 SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES USEFUL AS TACHYKININ ANTAGONISTS MERRELL PHARMA INC (US) 1997-09-24 EP disclosed
US-5661160-A ADMINISTERING AN ANTITUSSIVE AGENT FOR TREATING COUGH; TACHYKININ ANTAGONISM, SUBSTANCE P AND NEUROKININ A ANTAGONISM MERRELL PHARMACEUTICALS INC. (US) 1997-08-26 US disclosed
US-5648366-A TACHYKININ ANTAGONISTS USEFUL IN TREATING ASTHMA MERRELL PHARMACEUTICALS INC. (US) 1997-07-15 US disclosed
US-5635510-A TACHYKININ (ESPECIALLY SUBSTANCE P AND NEUROKININ A) ANTAGONISTS; ANTIINFLAMMATORY AGENTS, ANALGESICS; NERVOUS SYSTEM DISORDERS; BRONCHODILATOR AGENTS MERRELL PHARMACEUTICALS INC. (US) 1997-06-03 US disclosed
EP-0696280-A1 SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES USEFUL AS TACHYKININ ANTAGONISTS MERRELL DOW PHARMA (US) 1996-02-14 EP disclosed
WO-1994026735-A1 SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES USEFUL AS TACHYKININ ANTAGONISTS MERRELL DOW PHARMACEUTICALS INC. (US) 1994-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584765-B2 Polycyclic amines as sigma receptor modulators OPRM1, SIGMAR1, OPRK1 JAK2 638/4885JAK1 427/4885GPR119 385/4885
US-20240383853-A1 OXIMES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES GBA1, GBA2, GBA3 JAK2 3528/4885JAK1 4361/4885GPR119 42/4885
US-20230348467-A1 Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof PTPN11, PTPN1, PTPN7 JAK2 12/4885JAK1 27/4885GPR119 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.